Cargando…
Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China
Olaparib showed good efficacy and tolerability in the maintenance treatment of patients with initial therapy or high-grade serous recurrent ovarian cancer patients. This study aimed to analyze adverse events (AEs) of patients taking Olaparib and the quality of life (QoL) with Olaparib in 1 center of...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101289/ https://www.ncbi.nlm.nih.gov/pubmed/37058057 http://dx.doi.org/10.1097/MD.0000000000033434 |
_version_ | 1785025478208258048 |
---|---|
author | Jiang, Yi Xu, Ting Yuan, Lin Zhang, Lin Ruan, Xinjia Wu, Shan Meng, Huangyang Cheng, Wenjun |
author_facet | Jiang, Yi Xu, Ting Yuan, Lin Zhang, Lin Ruan, Xinjia Wu, Shan Meng, Huangyang Cheng, Wenjun |
author_sort | Jiang, Yi |
collection | PubMed |
description | Olaparib showed good efficacy and tolerability in the maintenance treatment of patients with initial therapy or high-grade serous recurrent ovarian cancer patients. This study aimed to analyze adverse events (AEs) of patients taking Olaparib and the quality of life (QoL) with Olaparib in 1 center of China. The study included 98 patients who received Olaparib and 210 patients without Olaparib from July 2018 to October 2021 for high-grade serous ovarian cancer in the Gynecology Oncology Department of Jiangsu Provincial Hospital. Information of clinicopathologic characteristics was collected from medical records. Then, we used the QLQ-C30 and Quality of Life Ovarian Cancer 28 Questionnaire (QLQ-OV28) to determine the QoL of 98 patients with and 210 patients without Olaparib. Among all 98 patients with Olaparib, 66 patients in first-line and 32 patients in more than second-line treatment. Regarding the best objective response with Olaparib maintenance in 78 patients with partial remission from most recent chemotherapy, 3 (3.84%) patients showed complete response (CR) and 6 (7.69%) showed as partial response (PR), whereas stable disease was observed in 42 patients (53.84%) and 27 patients (34.6%) showed as progression disease. AEs of Grade 3 and more were: anemia in 16 patients (16.32%), neutropenia in 20 patients (20.40%), thrombocytopenia in 4 patients (4.08%), and headache in 4 patients (4.08%). Dose reduction and drug discontinuation accounted for 73.40% and 20.40%, respectively. Olaparib as maintenance therapy increased QoL on all functioning domains and several symptom domains. Consistent with previous clinical trials, Olaparib maintenance therapy was proved safe and effective. Most patients may experience Grade 1 and 2 AEs. Olaparib maintenance therapy can increase QoL in several domains. |
format | Online Article Text |
id | pubmed-10101289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-101012892023-04-14 Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China Jiang, Yi Xu, Ting Yuan, Lin Zhang, Lin Ruan, Xinjia Wu, Shan Meng, Huangyang Cheng, Wenjun Medicine (Baltimore) 5600 Olaparib showed good efficacy and tolerability in the maintenance treatment of patients with initial therapy or high-grade serous recurrent ovarian cancer patients. This study aimed to analyze adverse events (AEs) of patients taking Olaparib and the quality of life (QoL) with Olaparib in 1 center of China. The study included 98 patients who received Olaparib and 210 patients without Olaparib from July 2018 to October 2021 for high-grade serous ovarian cancer in the Gynecology Oncology Department of Jiangsu Provincial Hospital. Information of clinicopathologic characteristics was collected from medical records. Then, we used the QLQ-C30 and Quality of Life Ovarian Cancer 28 Questionnaire (QLQ-OV28) to determine the QoL of 98 patients with and 210 patients without Olaparib. Among all 98 patients with Olaparib, 66 patients in first-line and 32 patients in more than second-line treatment. Regarding the best objective response with Olaparib maintenance in 78 patients with partial remission from most recent chemotherapy, 3 (3.84%) patients showed complete response (CR) and 6 (7.69%) showed as partial response (PR), whereas stable disease was observed in 42 patients (53.84%) and 27 patients (34.6%) showed as progression disease. AEs of Grade 3 and more were: anemia in 16 patients (16.32%), neutropenia in 20 patients (20.40%), thrombocytopenia in 4 patients (4.08%), and headache in 4 patients (4.08%). Dose reduction and drug discontinuation accounted for 73.40% and 20.40%, respectively. Olaparib as maintenance therapy increased QoL on all functioning domains and several symptom domains. Consistent with previous clinical trials, Olaparib maintenance therapy was proved safe and effective. Most patients may experience Grade 1 and 2 AEs. Olaparib maintenance therapy can increase QoL in several domains. Lippincott Williams & Wilkins 2023-04-14 /pmc/articles/PMC10101289/ /pubmed/37058057 http://dx.doi.org/10.1097/MD.0000000000033434 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | 5600 Jiang, Yi Xu, Ting Yuan, Lin Zhang, Lin Ruan, Xinjia Wu, Shan Meng, Huangyang Cheng, Wenjun Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China |
title | Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China |
title_full | Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China |
title_fullStr | Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China |
title_full_unstemmed | Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China |
title_short | Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China |
title_sort | analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with olaparib maintenance therapy: a single-center study in china |
topic | 5600 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101289/ https://www.ncbi.nlm.nih.gov/pubmed/37058057 http://dx.doi.org/10.1097/MD.0000000000033434 |
work_keys_str_mv | AT jiangyi analysisofadverseeventsandqualityoflifeinhighgradeserousovariancancerpatientswitholaparibmaintenancetherapyasinglecenterstudyinchina AT xuting analysisofadverseeventsandqualityoflifeinhighgradeserousovariancancerpatientswitholaparibmaintenancetherapyasinglecenterstudyinchina AT yuanlin analysisofadverseeventsandqualityoflifeinhighgradeserousovariancancerpatientswitholaparibmaintenancetherapyasinglecenterstudyinchina AT zhanglin analysisofadverseeventsandqualityoflifeinhighgradeserousovariancancerpatientswitholaparibmaintenancetherapyasinglecenterstudyinchina AT ruanxinjia analysisofadverseeventsandqualityoflifeinhighgradeserousovariancancerpatientswitholaparibmaintenancetherapyasinglecenterstudyinchina AT wushan analysisofadverseeventsandqualityoflifeinhighgradeserousovariancancerpatientswitholaparibmaintenancetherapyasinglecenterstudyinchina AT menghuangyang analysisofadverseeventsandqualityoflifeinhighgradeserousovariancancerpatientswitholaparibmaintenancetherapyasinglecenterstudyinchina AT chengwenjun analysisofadverseeventsandqualityoflifeinhighgradeserousovariancancerpatientswitholaparibmaintenancetherapyasinglecenterstudyinchina |